Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particles

Virus Research

Volumn 176, Issue 1-2, 2013, Pages 69-77

  Artpradit, Charlermchai ^a   Robinson, Luke N ^b   Gavrilov, Boris K ^b   Rurak, Troy T ^b   Ruchirawat, Mathuros ^a,c   Sasisekharan, Ram ^b  

^a Research and Innovation   (Thailand)

^b Massachusetts Institute of Technology   (United States)

^c Toxicology and Management of Chemicals   (Thailand)

Author keywords

Dengue; Heparan sulfate; Receptor; Recombinant subviral particle

Indexed keywords

DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HYALURONIC ACID;

ARTICLE; CELL SURFACE; DENGUE; DENGUE VIRUS 1; DOSE RESPONSE; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; VIRUS ATTACHMENT; VIRUS PARTICLE; VIRUS STRAIN;

ARTHROPODA; DENGUE VIRUS;

EID: 84881369273     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2013.04.017     Document Type: Article

References (56)

1. Alen M.M., Schols D. Dengue virus entry as target for antiviral therapy. Journal of Tropical Medicine 2012, 2012:628475.
2. Allison S.L., Tao Y.J., O'Riordain G., Mandl C.W., Harrison S.C., Heinz F.X. Two distinct size classes of immature and mature subviral particles from tick-borne encephalitis virus. Journal of Virology 2003, 77(21):11357-11366.
3. Anez G., Men R., Eckels K.H., Lai C.J. Passage of dengue virus type 4 vaccine candidates in fetal rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in rhesus macaques. Journal of Virology 2009, 83(20):10384-10394.
4. Cabrera Hernandez A., Smith D.R. Mammalian dengue virus receptors. Dengue Bulletin 2005, 29:16.
5. Carvalho S.E., Martin D.P., Oliveira L.M., Ribeiro B.M., Nagata T. Comparative analysis of American Dengue virus type 1 full-genome sequences. Virus Genes 2010, 40(1):60-66.
6. Chen Y., Maguire T., Hileman R.E., Fromm J.R., Esko J.D., Linhardt R.J., Marks R.M. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nature Medicine 1997, 3(8):866-871.
7. Corver J., Ortiz A., Allison S.L., Schalich J., Heinz F.X., Wilschut J. Membrane fusion activity of tick-borne encephalitis virus and recombinant subviral particles in a liposomal model system. Virology 2000, 269(1):37-46.
8. Dalrymple N., Mackow E.R. Productive dengue virus infection of human endothelial cells is directed by heparan sulfate-containing proteoglycan receptors. Journal of Virology 2011, 85(18):9478-9485.
9. Despres P., Frenkiel M.P., Ceccaldi P.E., Duarte Dos Santos C., Deubel V. Apoptosis in the mouse central nervous system in response to infection with mouse-neurovirulent dengue viruses. Journal of Virology 1998, 72(1):823-829.
10. Farrar J., Focks D., Gubler D., Barrera R., Guzman M.G., Simmons C., Kalayanarooj S., Lum L., McCall P.J., Lloyd L., Horstick O., Dayal-Drager R., Nathan M.B., Kroeger A. Towards a global dengue research agenda. Tropical Medicine and International Health 2007, 12(6):695-699.
11. Germi R., Crance J.M., Garin D., Guimet J., Lortat-Jacob H., Ruigrok R.W., Zarski J.P., Drouet E. Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology 2002, 292(1):162-168.
12. Gubler D.J. The economic burden of dengue. American Journal of Tropical Medicine and Hygiene 2012, 86(5):743-744.
13. Halstead S.B. Dengue. Lancet 2007, 370(9599):1644-1652.
14. Harris E., Videa E., Perez L., Sandoval E., Tellez Y., Perez M.L., Cuadra R., Rocha J., Idiaquez W., Alonso R.E., Delgado M.A., Campo L.A., Acevedo F., Gonzalez A., Amador J.J., Balmaseda A. Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. American Journal of Tropical Medicine and Hygiene 2000, 63(1/2):5-11.
15. Hidari K.I., Suzuki T. Dengue virus receptor. Tropical Medicine and Health 2011, 39(4 Suppl.):37-43.
16. Hidari K.I., Takahashi N., Arihara M., Nagaoka M., Morita K., Suzuki T. Structure and anti-dengue virus activity of sulfated polysaccharide from a marine alga. Biochemical and Biophysical Research Communications 2008, 376(1):91-95.
17. Hilgard P., Stockert R. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology 2000, 32(5):1069-1077.
18. Hoffman J., Larm O., Scholander E. A new method for covalent coupling of heparin and other glycosaminoglycans to substances containing primary amino groups. Carbohydrate Research 1983, 117:328-331.
19. Holmes D.A., Purdy D.E., Chao D.Y., Noga A.J., Chang G.J. Comparative analysis of immunoglobulin M (IgM) capture enzyme-linked immunosorbent assay using virus-like particles or virus-infected mouse brain antigens to detect IgM antibody in sera from patients with evident flaviviral infections. Journal of Clinical Microbiology 2005, 43(7):3227-3236.
20. Hsieh S.C., Liu I.J., King C.C., Chang G.J., Wang W.K. A strong endoplasmic reticulum retention signal in the stem-anchor region of envelope glycoprotein of dengue virus type 2 affects the production of virus-like particles. Virology 2008, 374(2):338-350.
21. Kato D., Era S., Watanabe I., Arihara M., Sugiura N., Kimata K., Suzuki Y., Morita K., Hidari K.I., Suzuki T. Antiviral activity of chondroitin sulphate E targeting dengue virus envelope protein. Antiviral Research 2010, 88(2):236-243.
22. Kuhn R.J., Zhang W., Rossmann M.G., Pletnev S.V., Corver J., Lenches E., Jones C.T., Mukhopadhyay S., Chipman P.R., Strauss E.G., Baker T.S., Strauss J.H. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002, 108(5):717-725.
23. Kuwahara M., Konishi E. Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens. Clinical and Vaccine Immunology 2010, 17(10):1560-1566.
24. Lee E., Lobigs M. Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus. Journal of Virology 2002, 76(10):4901-4911.
25. Lee E., Pavy M., Young N., Freeman C., Lobigs M. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Research 2006, 69(1):31-38.
26. Lee E., Wright P.J., Davidson A., Lobigs M. Virulence attenuation of Dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. Journal of General Virology 2006, 87(Pt 10):2791-2801.
27. Lin Y.L., Lei H.Y., Lin Y.S., Yeh T.M., Chen S.H., Liu H.S. Heparin inhibits dengue-2 virus infection of five human liver cell lines. Antiviral Research 2002, 56(1):93-96.
28. Liu W., Jiang H., Zhou J., Yang X., Tang Y., Fang D., Jiang L. Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties. Virus Genes 2010, 40(1):53-59.
29. Lok S.M., Kostyuchenko V., Nybakken G.E., Holdaway H.A., Battisti A.J., Sukupolvi-Petty S., Sedlak D., Fremont D.H., Chipman P.R., Roehrig J.T., Diamond M.S., Kuhn R.J., Rossmann M.G. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nature Structural & Molecular Biology 2008, 15(3):312-317.
30. Mandl C.W., Kroschewski H., Allison S.L., Kofler R., Holzmann H., Meixner T., Heinz F.X. Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo. Journal of Virology 2001, 75(12):5627-5637.
31. Marks R.M., Lu H., Sundaresan R., Toida T., Suzuki A., Imanari T., Hernaiz M.J., Linhardt R.J. Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors. Journal of Medicinal Chemistry 2001, 44(13):2178-2187.
32. Martinez-Barragan J.J., del Angel R.M. Identification of a putative coreceptor on Vero cells that participates in dengue 4 virus infection. Journal of Virology 2001, 75(17):7818-7827.
33. Miller N. Recent progress in dengue vaccine research and development. Current Opinion in Molecular Therapeutics 2010, 12(1):31-38.
34. Mondotte J.A., Lozach P.Y., Amara A., Gamarnik A.V. Essential role of dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation. Journal of Virology 2007, 81(13):7136-7148.
35. Ohtaki N., Takahashi H., Kaneko K., Gomi Y., Ishikawa T., Higashi Y., Kurata T., Sata T., Kojima A. Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate. Vaccine 2010, 28(40):6588-6596.
36. Okamoto K., Kinoshita H., Parquet Mdel C., Raekiansyah M., Kimura D., Yui K., Islam M.A., Hasebe F., Morita K. Dengue virus strain DEN2 16681 utilizes a specific glycochain of syndecan-2 proteoglycan as a receptor. Journal of General Virology 2011, 93(Pt 4):761-770.
37. Pattnaik P., Babu J.P., Verma S.K., Tak V., Rao P.V. Bacterially expressed and refolded envelope protein (domain III) of dengue virus type-4 binds heparan sulfate. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2007, 846(1/2):184-194.
38. Prestwood T.R., Prigozhin D.M., Sharar K.L., Zellweger R.M., Shresta S. A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. Journal of Virology 2008, 82(17):8411-8421.
39. Pujol C.A., Estevez J.M., Carlucci M.J., Ciancia M., Cerezo A.S., Damonte E.B. Novel dl-galactan hybrids from the red seaweed Gymnogongrus torulosus are potent inhibitors of herpes simplex virus and dengue virus. Antiviral Chemistry and Chemotherapy 2002, 13(2):83-89.
40. Puri B., Nelson W.M., Henchal E.A., Hoke C.H., Eckels K.H., Dubois D.R., Porter K.R., Hayes C.G. Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells. Journal of General Virology 1997, 78(Pt 9):2287-2291.
41. Qiu H., Tang W., Tong X., Ding K., Zuo J. Structure elucidation and sulfated derivatives preparation of two alpha-d-glucans from Gastrodia elata Bl. and their anti-dengue virus bioactivities. Carbohydrate Research 2007, 342(15):2230-2236.
42. Russell P.K., Brandt W.E., Dalrymple J.M. Chemical and antigenic structure of flaviviruses. The Tongaviruses 1980, 503-529. Academic Press, New York. R.W. Schlesinger (Ed.).
43. Sasisekharan R., Raman R., Prabhakar V. Glycomics approach to structure-function relationships of glycosaminoglycans. Annual Review of Biomedical Engineering 2006, 8:181-231.
44. Schalich J., Allison S.L., Stiasny K., Mandl C.W., Kunz C., Heinz F.X. Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions. Journal of Virology 1996, 70(7):4549-4557.
45. Shang W., Liu J., Yang J., Hu Z., Rao X. Dengue virus-like particles: construction and application. Applied Microbiology and Biotechnology 2012, 94(1):39-46.
46. Shiu S.Y., Jiang W.R., Porterfield J.S., Gould E.A. Envelope protein sequences of dengue virus isolates TH-36 and TH-Sman, and identification of a type-specific genetic marker for dengue and tick-borne flaviviruses. Journal of General Virology 1992, 73(Pt 1):207-212.
47. Simmons C.P., Farrar J.J., Nguyen v V., Wills B. Dengue. New England Journal of Medicine 2012, 366(15):1423-1432.
48. Talarico L.B., Damonte E.B. Interference in dengue virus adsorption and uncoating by carrageenans. Virology 2007, 363(2):473-485.
49. Talarico L.B., Pujol C.A., Zibetti R.G., Faria P.C., Noseda M.D., Duarte M.E., Damonte E.B. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antiviral Research 2005, 66(2/3):103-110.
50. Tang Y., Rodpradit P., Chinnawirotpisan P., Mammen M.P., Li T., Lynch J.A., Putnak R., Zhang C. Comparative analysis of full-length genomic sequences of 10 dengue serotype 1 viruses associated with different genotypes, epidemics, and disease severity isolated in Thailand over 22 years. American Journal of Tropical Medicine and Hygiene 2010, 83(5):1156-1165.
51. Thaisomboonsuk B.K., Clayson E.T., Pantuwatana S., Vaughn D.W., Endy T.P. Characterization of dengue-2 virus binding to surfaces of mammalian and insect cells. American Journal of Tropical Medicine and Hygiene 2005, 72(4):375-383.
52. Thepparit C., Phoolcharoen W., Suksanpaisan L., Smith D.R. Internalization and propagation of the dengue virus in human hepatoma (HepG2) cells. Intervirology 2004, 47(2):78-86.
53. Wang P.G., Kudelko M., Lo J., Siu L.Y., Kwok K.T., Sachse M., Nicholls J.M., Bruzzone R., Altmeyer R.M., Nal B. Efficient assembly and secretion of recombinant subviral particles of the four dengue serotypes using native prM and E proteins. PLoS ONE 2009, 4(12):e8325.
54. Watterson D., Kobe B., Young P.R. Residues in domain III of the dengue virus envelope glycoprotein involved in cell-surface glycosaminoglycan binding. Journal of General Virology 2012, 93(Pt 1):72-82.
55. Zhang S., Liang M., Gu W., Li C., Miao F., Wang X., Jin C., Zhang L., Zhang F., Zhang Q., Jiang L., Li M., Li D. Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice. Virology 2011, 8:333.
56. Zhu W., Li J., Liang G. How does cellular heparan sulfate function in viral pathogenicity?. Biomedical and Environmental Sciences 2011, 24(1):7.